Sign in5 stories
The filing details dose-dependent efficacy across primary and secondary endpoints and lays out plans for a Phase 2b/3 CSU study and a food allergy Phase 2 trial.
SEC filing
Cue disclosed a food allergy IND submission for CUE-221, a completed $50 million private placement, and higher quarterly expenses tied to a licensing deal, with cash of $17.4 million at quarter end.
SEC filing
The Boston biotech said Ahlers, a longtime life sciences finance executive, took the CFO role effective July 30, 2026, with a base salary of $450,000.
SEC filing
A Form D filed with the SEC shows Cue Biopharma raised nearly $50 million from four investors in an exempt offering dated July 13, 2026.
SEC filing
The financing, set to close July 13, 2026, was backed by Cormorant Asset Management and new investor Columbia Threadneedle Investments.
SEC filing